Rapt Therapeutics $RAPT Shares Bought by Comerica Bank

Comerica Bank raised its position in Rapt Therapeutics (NASDAQ:RAPT) by 53.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 89,327 shares of the company’s stock after buying an additional 31,287 shares during the period. Comerica Bank owned about 0.07% of Rapt Therapeutics worth $109,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Nuveen Asset Management LLC raised its position in Rapt Therapeutics by 50.5% in the fourth quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company’s stock valued at $185,000 after purchasing an additional 39,216 shares during the period. RTW Investments LP purchased a new stake in Rapt Therapeutics in the fourth quarter valued at approximately $18,587,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Rapt Therapeutics in the fourth quarter valued at approximately $63,000. Redmile Group LLC raised its position in Rapt Therapeutics by 1,183.4% in the fourth quarter. Redmile Group LLC now owns 6,475,317 shares of the company’s stock valued at $10,231,000 after purchasing an additional 5,970,785 shares during the period. Finally, Trustees of Columbia University in the City of New York purchased a new stake in Rapt Therapeutics in the fourth quarter valued at approximately $116,000. 99.09% of the stock is currently owned by institutional investors and hedge funds.

Rapt Therapeutics Stock Performance

Shares of RAPT opened at $16.22 on Friday. The company has a market capitalization of $268.25 million, a price-to-earnings ratio of -1.14 and a beta of -0.10. Rapt Therapeutics has a fifty-two week low of $5.67 and a fifty-two week high of $26.56. The firm has a 50-day simple moving average of $11.28 and a 200-day simple moving average of $9.23.

Rapt Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.04). Equities research analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on RAPT shares. Zacks Research downgraded shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 22nd. HC Wainwright boosted their target price on shares of Rapt Therapeutics to $27.00 and gave the stock a “buy” rating in a research note on Thursday, July 10th. Wall Street Zen upgraded shares of Rapt Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Lifesci Capital upgraded shares of Rapt Therapeutics to a “strong-buy” rating and set a $31.00 target price for the company in a research note on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. upgraded shares of Rapt Therapeutics from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research note on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.57.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.